According to the World Health Organization, of
all 50.5 million deaths recorded in 1990, 9.4 million were due to respiratory diseases. By 2020, of 68 million deaths, 11.9 million will be caused by Chronic Obstructive Pulmonary Disease (COPD), pneumonia, lung cancer or tuberculosis.
ILLUSTRATION: MOUNTAIN PEOPLE
Europe performs little better than the rest of the world. Respiratory diseases rank second (after cardiovascular diseases) in terms of mortality, incidence, prevalence and costs. In some countries, such as the United Kingdom, they are already the leading killer.
The European White Book on Lung Disease, published in 2003 by the European Respiratory Society and the European Lung Foundation, gathered epidemiological data for lung diseases from all European countries for the
first time. It provides a detailed
overview of the evolution of lung diseases in Europe, including data on morbidity, mortality and costs.
We have learned a great deal from this book. For example, lung cancer mortality rates for males fell slightly between 1960 and 1989 in some western European countries, such as Norway and Switzerland, but are still rising for females in almost all European countries. The prevalence of COPD, which is diagnosed mainly in smokers and former smokers, ranges from 2,000 per 100,000 inhabitants to more than 10,000, with mortality rates varying between 25 and 75 per 100,000.
Lung diseases are not just related to smoking. Genetic influences, along with nutritional, environmental and poverty-related factors, play key roles. But COPD is predicted to increase as a cause of death, along with lung cancer and TB.
Mortality rates
Epidemiological data for TB are the most complete, due to a surveillance system developed for all European countries. Whereas TB's incidence and mortality rates in western and central Europe are stable or declining, they have increased in eastern Europe during the last decade, due to deteriorating health-care systems.
Pneumonia will remain an important cause of death in Europe, with incidence currently ranging from 250 to more than 1,000 per 100,000 and mortality from 15 to 45 per 100,000.
Asthma has become increasingly prevalent in recent decades, affecting 2 percent to 20 percent of children in Europe, and between 5 percent and 10 percent of adults in western Europe. Reported mortality rates vary widely, the highest being more than eight per 100,000 in Portugal.
Data for other respiratory diseases are scarce. Interstitial lung diseases vary considerably in incidence and prevalence.
The prevalence of sleep-related diseases, for which data are available only from some of the western European countries, is less than 1,000 per 100,000 inhabitants in France, but more than 5,000 per 100,000 in Sweden. Available data on the incidence of cystic fibrosis, the most important hereditary lung disease, indicate a range of between five and ten per 100,000.
Where does respiratory disease kill most often? According to the data collected in the White Book, the age-standardized mortality rate per 100,000 inhabitants is highest in Kyrgyzstan, at 165, and lowest in Austria, at 30. The European average stands at 65, while the EU average is 57. Ireland and the UK suffer some of the highest rates -- 120 and 105, respectively -- whereas other western European and most central European countries remain below the average.
As the incidence of lung disease rises, so will its costs. The total annual financial burden of respiratory diseases in Europe is approximately 100 billion euros, with COPD accounting for almost half of the total, followed by asthma, pneumonia, lung cancer and TB.
Inpatient care is just the tip of the iceberg, amounting to 17.8 billion euros annually. Surprisingly, the annual number of hospital days is higher in western Europe than in central and eastern Europe (11.1 versus 7.2 per 100,000 population), while average daily hospital costs in western Europe are almost 10 times higher (310 euros versus 32 euros). Other costs include ambulatory care (9.2 billion euros), drug supplies (6.7 billion euros), and mortality and rehabilitation (20 billion euros).
Lost productivity
The largest single cost by far,
estimated at 48.3 billion euros,
is indirect: lost productivity. The total number of workdays lost due to respiratory diseases was 66.2 per 100,000 inhabitants in western Europe -- more than four times higher than the rate
of 15.4 in central and eastern Europe. As with hospital stays,
so with workdays: higher
productivity in western Europe compounds the cost.
Because lung diseases are so important, preventive measures, early detection and treatment must be reinforced. This will necessitate not only improvements in direct patient care, but also in basic and clinical research as well as in teaching and training.
Across Europe, there are huge differences in the number of specialists in respiratory medicine,
as well as in the number of lung researchers at the university level. The number of chest physicians per 100,000 inhabitants is only 0.8 in the UK, but 10.4 in Greece, with a European average of 3.2. The same is true of respiratory medicine at the university level, where the European average is 0.06
per 100,000 inhabitants, but
varies from 0.04 per 100,000 in
Poland, Russia, Romania, Austria, Germany and the UK to more
than 0.08 per 100,000 in Norway, Finland, and Ireland.
Given the scale of their human and economic costs, managing lung diseases should become a high priority for all European countries.
Robert Loddenkemper is a professor of medicine at Charite-Universitatsmedizin Berlin. He is chief editor of the European Lung White Book, the first comprehensive survey on respiratory health in Europe.
Copyright: Project Syndicate
Could Asia be on the verge of a new wave of nuclear proliferation? A look back at the early history of the North Atlantic Treaty Organization (NATO), which recently celebrated its 75th anniversary, illuminates some reasons for concern in the Indo-Pacific today. US Secretary of Defense Lloyd Austin recently described NATO as “the most powerful and successful alliance in history,” but the organization’s early years were not without challenges. At its inception, the signing of the North Atlantic Treaty marked a sea change in American strategic thinking. The United States had been intent on withdrawing from Europe in the years following
My wife and I spent the week in the interior of Taiwan where Shuyuan spent her childhood. In that town there is a street that functions as an open farmer’s market. Walk along that street, as Shuyuan did yesterday, and it is next to impossible to come home empty-handed. Some mangoes that looked vaguely like others we had seen around here ended up on our table. Shuyuan told how she had bought them from a little old farmer woman from the countryside who said the mangoes were from a very old tree she had on her property. The big surprise
Ursula K. le Guin in The Ones Who Walked Away from Omelas proposed a thought experiment of a utopian city whose existence depended on one child held captive in a dungeon. When taken to extremes, Le Guin suggests, utilitarian logic violates some of our deepest moral intuitions. Even the greatest social goods — peace, harmony and prosperity — are not worth the sacrifice of an innocent person. Former president Chen Shui-bian (陳水扁), since leaving office, has lived an odyssey that has brought him to lows like Le Guin’s dungeon. From late 2008 to 2015 he was imprisoned, much of this
The issue of China’s overcapacity has drawn greater global attention recently, with US Secretary of the Treasury Janet Yellen urging Beijing to address its excess production in key industries during her visit to China last week. Meanwhile in Brussels, European Commission President Ursula von der Leyen last week said that Europe must have a tough talk with China on its perceived overcapacity and unfair trade practices. The remarks by Yellen and Von der Leyen come as China’s economy is undergoing a painful transition. Beijing is trying to steer the world’s second-largest economy out of a COVID-19 slump, the property crisis and